Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS

Weijun Fu,Wei Li,Jianda Hu,Gang An,Yafei Wang,Chengcheng Fu,Lijuan Chen,Jie Jin,Xinan Cen,Zheng Ge,Zhen Cai,Ting Niu,Ming Qi,Xue Gai,Qian Li,Weiping Liu,Wenyu Liu,Xue Yang,Xi Chen,Jin Lu

Clinical Lymphoma Myeloma and Leukemia（2023）

引用 1|浏览19

暂无评分

摘要

•Chinese patients with relapsed/refractory multiple myeloma were given D-Vd or Vd•With longer follow-up, D-Vd maintained efficacy benefits and consistent safety•Efficacy and safety results were consistent with the global CASTOR study•Results support D-Vd for Chinese patients with relapsed/refractory multiple myeloma

查看译文

关键词

CD38,monoclonal antibody,efficacy,safety,Asian

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要